Baguley, B. C., 95
Balabhadrapathruni, S., 123
Bando, Y., 289
Barbieri, F., 455
Barsotti, B. P., 55
Bernard-Poenaru, O., 137
Berthois, Y., 137
Bianchi, N., 279
Biedler, J. L., 87
Billson, F. A., 103
Bloomer, W. D., 47, 561
Bobrowska-Hägerstrand, M., 463
Bogliolo, G., 55
Bonner, E., 551
Borgatti, M., 279
Borowski, E., 245
Botta, M., 55
Boucaud, M., 211
Bouizar, Z., 137
Braca, III, J. A., 87
Breda, L., 279
Bressolle, F., 211
Bruzzo, C., 455
Bustuoabad, O. D., 147

Cataisson, C., 137
Chan, P. K. S., 161
Chang, C.-C., 353
Chang, R. L., 169
Chen, C.-T., 199
Chen, G. C., 161
Chevassut, T., 373
Ching, L.-M., 95
Cho, Y. M., 137
Chun, K.-S., 37
Claret, F.-X., 399
Clarke, A. R., 333
Conney, A. H., 61, 169
Conway, R. M., 103
Cortes, D., 521
Costes, N., 191
Cros, M., 137
Cross, H. S., 551
Cui, X. X., 169
Culine, S., 211
Cutts, S. M., 479

Dabelsteen, S., 393
D'Agnano, I., 25
de Bruijin, M., 315
Deng, H.-K., 359
Denne, M., 137
Denny, W. A., 491
DePedro, N., 521
De Vernejoul, M.-C., 137
Diamandis, E. P., 381
Díaz, G. S., 147
di Gianni, P. D., 147
Dinçer, Y., 205
Dufat, H., 191
Dupont, F., 437
Dziadyk, J. M., 113
Dzierzak, E., 315

El-Gewely, M. R., 429
Ellis, M. J., 175
Elomri, A., 191
Estornell, E., 521

Fan, W., 113
Fang, Y., 113
Feliciano, C., 405
Ferguson, J., 503
Ferguson, L. R., 491
Foley, J., 137
Folkers, G., 513
Fortunel, N. O., 445
Franco, M., 147
Fraser, J. D., 95

Gallo, M. A., 123
Gambari, R., 279
Gancberg, D., 437
Gartel, A. L., 405
Geromichalos, G., 261
Gigis, P., 261
Gogusoy, G., 205
Gomeni, R., 211
Graulet, A.-M., 137
Gray, P. J., 479
Gridley, D. S., 9
Grion, L. C., 147
Guillaumel, J., 537
Gulisano, F., 19
Gulisano, M., 19
Gurdon, J. B., 301

Hägerstrand, H., 463
Halaban, R., 3
Hardwick, J., 71, 79
Hatzfeld, A., 445
Hatzfeld, J. A., 445
Hein, A. M., 87
Hockl, P., 147
Horth, M., 437
Huang, B.-R., 471
Huang, S.-T., 199
Huang, Y., 113
Humeniuk, R., 269

Ji, M., 47, 561

Kaczmarek, ?, 269
Kajioka, E. H., 9
Kállay, E., 551
Kanematsu, T., 289
Kang, M., 37
Karim, A., 437
Kathuria, H., 71
Kelland, L. R., 503
Kimura, K., 479
King, N. J. C., 103
Klein, C. D. P., 513
Koch, M., 191
Komatsu, F., 235
Kordon, E. C., 147
Kotaka, M., 161
Kraus, M., 359
Kumar, R., 221
Kuo, H.-S., 199

Laccetti, P., 25
Lai, P. B. S., 161
Lampronti, I., 279
Lau, W. Y., 161
Laughton, C. A., 175
Lazo, J. S., 347
Lee, J., 37
Lee, K.-H., 471
Léonce, S., 191
Léonce, S., 537
Lerza, R., 55
Leung, T. W. T., 161
Li, A. K. C., 161
Li, X., 323
Li, X.-H., 61
Lim, B., 323, 373
Lin, C.-M., 199
Lin, Y., 61
Lin, Y.-L., 199
Liu, H.-Y., 359
Liu, L.-Q., 359
Loghmani, F., 71
Lombardi, M. G., 147
Lou, Y.-R., 61
Lown, J. W., 221
Lu, Y.-P., 61

Ma, X., 315
Madigan, M. C., 103
Mansouri, A., 399
Marcinkowska, E., 269
Meiss, R. P., 147
Michalak, K., 463
Michel, S., 191
Miller, G. M., 9
Mischiati, C., 279
Missailidis, S., 175
Modi, C., 175
Mohammed, K. A., 71, 79
Molnár, J., 463
Monier, M.-N., 445
Monneret, C., 537
Motohashi, N., 463
Mrówczynski, L., 463

Nasreen, N., 71, 79
Nastruzzi, C., 279
Natsis, K., 261
Norris, J. S., 113
Nosetto, S. H., 147
Novelli, F., 455

Olsen, J., 393
Önen, S., 205
Ottersbach, K., 315

Pacini, S., 19
Paine, M. J. I., 245
Palmer, B. D., 95
Pampalakis, G., 381
Pannacciulli, I., 55
Papadopoulou, M. V., 47, 561
Papadopoulou, M. V., 561
Pappas, I. S., 339
Park, K.-K., 37
Pasqualini, C. D., 147
Paterson, L., 303
Pawlowska, J., 245
Pearson, V. C., 503
Peczynska-Czoch, W., 269
Pedone, C., 279
Peláez, F., 521
Penfold, P. L., 103
Peng, Y.-C., 199
Peruchon, L., 537
Peterlik, M., 551
Pfeiffer, B., 191, 537
Phillips, D. R., 479
Pierré, A., 191, 537
Pinguet, F., 211
Portella, G., 25
Poujol, S., 211
Promyart, P., 253

Sahpazidou, D., 261
Sanders, K., 71, 79
Sansom, O. J., 333
Sardi, I., 19
Saviano, M., 279
Scammell, J. G., 87
Schenone, E., 55
Seguin, E., 191
Serfas, M. S., 409
Shi, M.-J., 359
Shih, W. J., 61
Shirataki, Y., 463
Simillides, G., 381
Söderström, T., 463
Sone, S., 289
Sorrentino, R., 25
Sotiropoulou, G., 381
Spalletti-Cernia, D., 25
Sparatore, A., 455
Sparatore, F., 455
Spegelaere, P., 437
Spencer, D. M. S., 479
Spengler, B. A., 87
Sposato, M., 359
Sriram, P. S., 79
Stanslas, J., 175
Stevens, M. F. G., 175
Stevens, Z., 359
Strair, R., 169
Stravoravdi, P., 261
Surh, Y.-J., 37
Suthiphongchai, T., 253

Tarasiuk, J., 245
Thakker, R. V., 551
Thampatty, B. P., 529
Thomas, T. J., 123
Thomas, T., 123
Tian, L., 399
Tillequin, F., 191
Tohtong, R., 253
Toliou, T., 261
Tormo, J. R., 521
Tortum, O. B., 205
Troelsen, J. T., 393
Trosko, J. E., 353
Truini, M., 55
Tsai, H.-D., 199
Tsetsenis, T., 381
Tsiftsoglou, A. S., 339
Tsujishita, Y., 421
Tyner, A. L., 405, 409

Uehara, H., 289

van der Horn, K., 315
Van Horn, R. D., 71, 79
Vanzulli, S. I., 147
Vaudrain, T., 359
Vecchio, G., 25
Virochrut, S., 253
Visser, J., 359
Vizirianakis, I. S., 339

Wakayama, T., 309
Weir, I. E., 491
Whiteside, G., 491
Wilairat, P., 253
Wilmut, I., 303
Wipf, P., 347
Wolf, C. R., 245
Woodward, D., 169
Woon, S.-T., 95
Wrba, F., 551
Wróbel, A., 463

Xie, J.-G., 61
Xu, H., 429

Yano, S., 289
Yiotakis, A., 381

Zafiriou, G., 261
Zafiropoulos, N., 381
Zeicher, M., 437
Zhang, Q., 399
Zheng, X., 169
Zupi, G., 25

Barminomycin, 479
Basic ether, 537
BCPCF, 463
Benzbromarone, 463
Benz[5,6]isoindolo[2,1-a]indole, 537
Benzo[b]acronycine, 191
Bioassay, 169
Bioreductive drugs, 561
bis-Aziridinylnaphthoquinone derivatives, 199
Bisbenzimidazole, 491
bis(ethyl)Polyamines, 123
Blood levels, 169
Breast cancer, 137
BRK, 409

Caco-2 cells, 551
Cancer, 521, 537
Cancer and RhoGTPases, 323
Cancer biomarkers, 381
Cancer therapy, 437
CaR gene expression, 551
Caspase 3, 61
CC chemokine receptor 6 (CCR6), 393
CD4/CD8 ratio, 9
CD44 receptor, 71
Cell-cell adhesion killing, 235
Cell cycle, 269, 491
Cell growth, 19
Cell signaling pathways, 347
Cellular phone, 19
Chemoprevention, 61, 261
Chemoresistance, 399
Chemotherapeutic agents, 561
Chromogranins, 87
Circular dichroism, 175
Cisplatin, 399
Clone, 309
Colon carcinoma progression, 551
Connexins, 353
Costimulation, 437
COX-2 inhibition, 529
Cysteaminylphenol, 503
Cytokines, 137
Cytotoxic activity, 455
Cytotoxicity, 191, 221, 269, 521

Decoy, 279
Development program, 339
Dexamethasone, 87
6-Diakylaminoalkylamino side chains, 191
Diarylheptanoids, 37
Differential display, 429
Differentiation, 87, 103, 309, 339
Disease model, 309
DNA adducts, 479
DNA alkylation, 199
DNA binding, 175
DNA minor groove binders, 221
DNA repair, 205
DNMT3A, 373
Doxorubicin, 479
Drug resistance, 25, 205
Drug uptake, 95

Early killing, 235
Embryo, 315
Embryo stem cells, 303
Embryonal mass, 147
Embryonic stem cell(s), 309, 373
Endothelial cells, 359
Endothelium, 315
Enterocytes, 393
Epidermal growth factor receptor (EGFR), 289
Etoposide, 269
Evolution of multicellular organisms, 353
Expression profile(s), 393, 429
Extracellular signal-regulated kinase (ERK), 253 

b-Galactosidase, 405
Gap junctions, 353
Gastric tumors, 205
Gene expression, 19
Gene expression and mutation, 323
Genetic changes, 3
Glucocorticoid, 87
Granulomatosis, 55
GTPase regulators and effectors, 323

Haptotaxis, 71
Hematopoietic stem cells, 315, 339, 445
Hepatitis C virus, 161
Hepatocellular carcinoma, 161
HER2, 289
Hormone regulation, 147
Human kallikrein 6, 381
Human kallikrein 13, 381
Human neuroblastoma, 87
Hyaluronan, 71
Hypoxic cytotoxins, 47

Immunohistochemistry, 289
Immunotherapy, 103
Indoloquinolines, 269
Indomethacin, 463
Inhibitory RhoGTPases, 323
Insulin-like growth factor binding protein-3, 359
Intercalating agent, 537
Invasion, 253
IPP5C domain, 421
Irreversible inhibitors, 513
Isoindolo[2,1-a]indole, 537

Keratinocytes, 393
Killikreins, 381

LAK cells, 235
Late killing, 235
Limited sampling strategy, 211
Lung tumor, 9
Lymphoma, 55
Lysosome, 235

Malignant mesothelioma, 71
Mast cells, 103
MCF-7, 455
MDA-MB 231, 455
Membrane potentials, 25
Mesothelial cells, 79
Metabolic changes, 3
Metalloproteinases, 137
Metastases-derived thyroid cells, 25
Metastasis, 253
a-Methylene-g-butyrolactone, 471
Methionine aminopeptidase, 513
Methylation, 373
O⁶-Methylguanine DNA methyltransferase, 205
MHC-II, 103
Microglia, 103
Microinjection, 309
Mitochondrial respiratory chain inhibitors, 521
Mitotic arrest, 113
Molecular dynamics simulation, 513
Mouse skin tumor promotion, 37
Multidrug resistance, 463
Multivariate analysis, 289
Murine erythroleukemia cells, 339
Murine small intestine, 333
Murine tumors, 147
Mutation(s), 405, 429
Myelocytic leukemia, 169

N-myc, 87
NADH dehydrogenase, 245
NADPH cytochrome P450 reductase, 245
NF-kB, 95
NF-kB/IkB, 113
Nitrogen mustard, 491
NKT cells, 9
NLCPQ-1, 561
NLCQ-1, 47
Non-Hodgkin's lymphoma, 55
Nonionizing radiation, 19
Non-small cell lung cancer, 289
Nuclear transfer (nt), 309
Nuclear transfer, 303

Oncoselective, 437
Ovarian cancer cells, 79
Ovarian carincoma, 399

Rak, 409
ras transformation, 25
Real-time PCR, 479
Red blood cell, 463
Reproductive cloning, 303
Reprogramming, 309
Retina, 103
Retrovirus, 405
Runx1, 315

Saliva, 211
Self-renewal, 445
Serine proteases, 381
Sigma receptor ligands, 455
Signal transduction, 253, 551
Signaling domains, 421
Sik, 409
Small molecules, 347
Somatic cells, 303
Spectrophotometric analysis, 175
Spontaneous tumors, 261
Src42A, 409
Srm, 409
START domain, 421
Stem cell diseases, 353
Stem cell expansion in vitro, 359
Structural genomics, 421
Structure-activity analysis, 463
Structure-activity relationship, 529
Suppression subtractive hybridization, 161
Synergism, 47

Taxol, 47
tet, 373
12-O-Tetradecanoylphorbol-13-acetate (TPA), 169
Therapeutic cloning, 303
Thymidine kinase, 437
Tirapazamine, 47
T lymphocytes, 9
Topoisomerase I, 491
Topoisomerase II, 269
Topotecan, 211
Total-body irradiation, 9
Transcription, 405
Transforming growth factor-b, 445
Transient expression, 429
Tumor cell line growth inhibitors, 521
Tumor dormancy, 147
Tumor hypoxia, 199
Tumor predisposition, 333
Tumor suppressor activity, 333
Tyrosinase, 3, 503

UV, 175
UV carcinogenesis, 61

Vascular endothelial growth factor, 79
Vaculature, 103
Vector, 437
Verapamil, 25

Wittig reaction, 537

Xanthine oxidase, 245
XIAP, 399

Yakuchinone, 37